Prednisone and deflazacort in Duchenne muscular dystrophy: The Cincinnati Study
This webinar highlights a summary of an article about the Cincinnati study, which was published in the Journal of Comparative Effectiveness Research in January 2020. The study researchers wanted to further understand the differences between using prednisone and deflazacort in males with DMD by reviewing data from past medical records of patients seen in clinics rather than in clinical studies. This is known as gathering real-world evidence. In the Cincinnati study, the researchers compared males with DMD who started taking prednisone as their first steroid treatment with males who started taking deflazacort as their first steroid treatment.
Courtney Shellenbarger, NP
Courtney has been working side-by-side with Dr. Wong for more than six years. In May 2018, she moved from Ohio to Massachusetts to help launch the Duchenne Program. As a pediatric nurse practitioner with more than 10 years of experience, Courtney sees and treats patients, but she also plays a big role behind the scenes to help keep the program’s gears moving smoothly. She loves collaborating with her colleagues to deliver top-notch care to patients and their families. “Our core team works together so closely, it’s kind of like we’re all part of the same brain.”
Hawken Miller is a 25-year-old with Duchenne Muscular Dystrophy. He is a journalist by trade and is a speaker, columnist, tweeter and videographer on the side. Hawken works for BioNews, freelances for The Washington Post, and writes a weekly column called “Hawk’s-Eye View” for Muscular Dystrophy News Today and is a spokesperson for CureDuchenne. He graduated from the University of Southern California with honors in May 2019, where he majored in journalism. While at USC, he was an editor at The Daily Trojan and USC Annenberg Media. Hawken interned at KTLA 5 News, the Sacramento Bee and The Orange County Register. When he isn’t writing, Hawken loves talking about, playing and watching video games and everything Star Wars.